Formulary Search Results for: CALCIUM AND VITAMIN D
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indications:
Breast cancer
- As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received one or more prior anti-HER2-based regimens.
- As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Prescribing Notes:
Trastuzumab deruxtecan is currently non-formulary for the following indications:
- Gastric or gastroesophageal junction adenocarcinoma: As monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
- Non-small cell lung cancer: As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
- Breast cancer: Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultra low breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
- Treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.
1.2 Antispasmodics and other drugs altering gut motility - View Category
Prescribing Notes:
In April 2014, the MHRA issued advice to healthcare professionals relating to the use of domperidone, restricting its use to relief or nausea and vomiting, advising that it should be used at the lowest effective dose for the shortest possible time, and highlighting changes to the contraindications, dosing and duration of treatment of the medicine.
Domperidone is no longer licensed in patients weighing less than 35 kg because of a lack of evidence for benefit. See this MHRA alert for further information and a reminder of contraindications.
4.6 Drugs used in nausea and vertigo - View Category
Prescribing Notes:
In April 2014, the MHRA issued advice to healthcare professionals relating to the use of domperidone, restricting its use to relief or nausea and vomiting, advising that it should be used at the lowest effective dose for the shortest possible time, and highlighting changes to the contraindications, dosing and duration of treatment of the medicine.
Domperidone is no longer licensed in patients weighing less than 35 kg because of a lack of evidence for benefit. See this MHRA alert for further information and a reminder of contraindications.
4.6 Drugs used in nausea and vertigo - View Category
Restrictions:
Restricted to use by consultant anaesthetists for use as a third line antiemetic for post-operative nausea and vomiting (PONV) in patients with previous failure of other formulary agents. This preparation should only be routinely held in theatre recovery areas for this indication. The use of droperidol for addition to a PCA containing opiates remains non-Formulary.
4.7.2 Opioid analgesics - View Category
Restrictions:
Excludes DF118 Forte®, Remedeine®, and Remedeine Forte® and their generic equivalents.
Prescribing Notes:
Dihydrocodeine is generally not an effective analgesic for post-operative pain except in neurosurgical procedures where NSAIDs are contraindicated when it avoids undue sedation and confusion which might interfere with neurological appraisal.
4.9.1 Dopaminergic drugs used in Parkinson’s disease - View Category
Restrictions:
Restricted to specialist use only for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
6.1.2.2 SGLT2 Inhibitors - View Category
Restrictions:
Restricted to use only in adult patients for whom a combination of dapagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
7.3.2.1 Oral progestogen-only contraceptives - View Category
7.4.1 Drugs for urinary retention - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Only suitable for patients with enlargement of the prostate.